Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K‐RAS status for unresectable colorectal liver metastasis (BECK study): Long‐term results of survival
Background/Purpose To investigate the long‐term outcome and entire treatment course of patients with technically unresectable CRLM who underwent conversion hepatectomy and to examine factors associated with conversion to hepatectomy. Methods Recurrence and survival data with long‐term follow‐up were...
Gespeichert in:
| Veröffentlicht in: | Journal of hepato-biliary-pancreatic sciences 2020-08, Vol.27 (8), p.496-509 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 509 |
|---|---|
| container_issue | 8 |
| container_start_page | 496 |
| container_title | Journal of hepato-biliary-pancreatic sciences |
| container_volume | 27 |
| creator | Okuno, Masayuki Hatano, Etsuro Toda, Rei Nishino, Hiroto Nakamura, Kojiro Ishii, Takamichi Seo, Satoru Taura, Kojiro Yasuchika, Kentaro Yazawa, Takefumi Zaima, Masazumi Kanazawa, Akiyoshi Terajima, Hiroaki Kaihara, Satoshi Adachi, Yukihito Inoue, Naoya Furumoto, Katsuyoshi Manaka, Dai Tokuka, Atsuo Furuyama, Hiroaki Doi, Koji Hirose, Tetsuro Horimatsu, Takahiro Hasegawa, Suguru Matsumoto, Shigemi Sakai, Yoshiharu Uemoto, Shinji |
| description | Background/Purpose
To investigate the long‐term outcome and entire treatment course of patients with technically unresectable CRLM who underwent conversion hepatectomy and to examine factors associated with conversion to hepatectomy.
Methods
Recurrence and survival data with long‐term follow‐up were analyzed in the cohort of a multi‐institutional phase II trial for technically unresectable colorectal liver metastases (the BECK study).
Results
A total of 22/12 patients with K‐RAS wild‐type/mutant tumors were treated with mFOLFOX6 + cetuximab/bevacizumab. The conversion R0/1 hepatectomy rate was significantly higher in left‐sided primary tumors than in right‐sided tumors (75.0% vs 30.0%, P = .022). The median follow‐up was 72.6 months. The 5‐year overall survival (OS) rate in the entire cohort was 48.1%. In patients who underwent R0/1 hepatectomy (n = 21), the 5‐year RFS rate and OS rate were 19.1% and 66.3%, respectively. At the final follow‐up, seven patients had no evidence of disease, five were alive with disease, and 20 had died from their original cancer. All 16 patients who achieved 5‐year survival underwent conversion hepatectomy, and 11 of them underwent further resection for other recurrences (median: 2, range: 1‐4).
Conclusions
Conversion hepatectomy achieved a similar long‐term survival to the results of previous studies in initially resectable patients, although many of them experienced several post‐hepatectomy recurrences. Left‐sided primary was found to be the predictor for conversion hepatectomy.
Highlight
Okuno and colleagues report the final survival analysis of a multi‐institutional phase II trial for initially technically unresectable colorectal liver metastasis (BECK study). The 5‐year overall survival rate was 66.3% in patients who underwent conversion hepatectomy, which was the only independent prognostic factor for better overall survival on multivariate analysis. |
| doi_str_mv | 10.1002/jhbp.747 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2398158293</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2435350586</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4517-ed23bcdcc86f187713b4b984debbfc274ca27e959f8c39e8777ba738be96af343</originalsourceid><addsrcrecordid>eNp1kctu1DAUhiMEolWpxBMgS2zKIm1sJ7HDrh11KO1Ig7hI7CLbOaEeOfHUlynDikfgjXgXngRH04uEhDf2sT5_58h_lr3ExTEuCnKyupbrY1ayJ9k-5jXP64aTpw9nVu5lh96virQopg0tnmd7lNCaFJjvZ79ndtyA89qOKFik7LA2EAA58KDCdHurwzUa5svFfPm13lUSNkLpH3EQElmHFIT4XU-FFB46lB5d_fn56-PpJ-SDCNGjPlFx3DmFNJD6GOumwiCjU380QBAJ9tqjo7Pz2VV6Gbvtm7doYcdvSRbADdNQ0QSPbI98dBu9EeZF9qwXxsPh3X6QfZmff55d5Ivlu_ez00WuygqzHDpCpeqU4nWPOWOYylI2vOxAyl4RVipBGDRV03NFG0gEk4JRLqGpRU9LepAd7bxrZ28i-NAO2iswRoxgo28JbTiuOGloQl__g65sdGOariUlrWhVVLx-FCpnvXfQt2uX_tBtW1y0U67tlGubck3oqzthlAN0D-B9ignId8CtNrD9r6i9vDj7MAn_AsDjsag</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2435350586</pqid></control><display><type>article</type><title>Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K‐RAS status for unresectable colorectal liver metastasis (BECK study): Long‐term results of survival</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Okuno, Masayuki ; Hatano, Etsuro ; Toda, Rei ; Nishino, Hiroto ; Nakamura, Kojiro ; Ishii, Takamichi ; Seo, Satoru ; Taura, Kojiro ; Yasuchika, Kentaro ; Yazawa, Takefumi ; Zaima, Masazumi ; Kanazawa, Akiyoshi ; Terajima, Hiroaki ; Kaihara, Satoshi ; Adachi, Yukihito ; Inoue, Naoya ; Furumoto, Katsuyoshi ; Manaka, Dai ; Tokuka, Atsuo ; Furuyama, Hiroaki ; Doi, Koji ; Hirose, Tetsuro ; Horimatsu, Takahiro ; Hasegawa, Suguru ; Matsumoto, Shigemi ; Sakai, Yoshiharu ; Uemoto, Shinji</creator><creatorcontrib>Okuno, Masayuki ; Hatano, Etsuro ; Toda, Rei ; Nishino, Hiroto ; Nakamura, Kojiro ; Ishii, Takamichi ; Seo, Satoru ; Taura, Kojiro ; Yasuchika, Kentaro ; Yazawa, Takefumi ; Zaima, Masazumi ; Kanazawa, Akiyoshi ; Terajima, Hiroaki ; Kaihara, Satoshi ; Adachi, Yukihito ; Inoue, Naoya ; Furumoto, Katsuyoshi ; Manaka, Dai ; Tokuka, Atsuo ; Furuyama, Hiroaki ; Doi, Koji ; Hirose, Tetsuro ; Horimatsu, Takahiro ; Hasegawa, Suguru ; Matsumoto, Shigemi ; Sakai, Yoshiharu ; Uemoto, Shinji</creatorcontrib><description>Background/Purpose
To investigate the long‐term outcome and entire treatment course of patients with technically unresectable CRLM who underwent conversion hepatectomy and to examine factors associated with conversion to hepatectomy.
Methods
Recurrence and survival data with long‐term follow‐up were analyzed in the cohort of a multi‐institutional phase II trial for technically unresectable colorectal liver metastases (the BECK study).
Results
A total of 22/12 patients with K‐RAS wild‐type/mutant tumors were treated with mFOLFOX6 + cetuximab/bevacizumab. The conversion R0/1 hepatectomy rate was significantly higher in left‐sided primary tumors than in right‐sided tumors (75.0% vs 30.0%, P = .022). The median follow‐up was 72.6 months. The 5‐year overall survival (OS) rate in the entire cohort was 48.1%. In patients who underwent R0/1 hepatectomy (n = 21), the 5‐year RFS rate and OS rate were 19.1% and 66.3%, respectively. At the final follow‐up, seven patients had no evidence of disease, five were alive with disease, and 20 had died from their original cancer. All 16 patients who achieved 5‐year survival underwent conversion hepatectomy, and 11 of them underwent further resection for other recurrences (median: 2, range: 1‐4).
Conclusions
Conversion hepatectomy achieved a similar long‐term survival to the results of previous studies in initially resectable patients, although many of them experienced several post‐hepatectomy recurrences. Left‐sided primary was found to be the predictor for conversion hepatectomy.
Highlight
Okuno and colleagues report the final survival analysis of a multi‐institutional phase II trial for initially technically unresectable colorectal liver metastasis (BECK study). The 5‐year overall survival rate was 66.3% in patients who underwent conversion hepatectomy, which was the only independent prognostic factor for better overall survival on multivariate analysis.</description><identifier>ISSN: 1868-6974</identifier><identifier>EISSN: 1868-6982</identifier><identifier>DOI: 10.1002/jhbp.747</identifier><identifier>PMID: 32362018</identifier><language>eng</language><publisher>Japan: Wiley Subscription Services, Inc</publisher><subject>Colorectal cancer ; colorectal liver metastases ; conversion therapy ; hepatic resection ; Immunotherapy ; Monoclonal antibodies ; repeat hepatectomy ; sidedness ; Targeted cancer therapy ; Tumors</subject><ispartof>Journal of hepato-biliary-pancreatic sciences, 2020-08, Vol.27 (8), p.496-509</ispartof><rights>2020 Japanese Society of Hepato‐Biliary‐Pancreatic Surgery</rights><rights>This article is protected by copyright. All rights reserved.</rights><rights>Copyright © 2020 Japanese Society of Hepato‐Biliary‐Pancreatic Surgery</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4517-ed23bcdcc86f187713b4b984debbfc274ca27e959f8c39e8777ba738be96af343</citedby><cites>FETCH-LOGICAL-c4517-ed23bcdcc86f187713b4b984debbfc274ca27e959f8c39e8777ba738be96af343</cites><orcidid>0000-0001-5708-6384 ; 0000-0001-9539-8098 ; 0000-0003-3407-1918</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjhbp.747$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjhbp.747$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32362018$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Okuno, Masayuki</creatorcontrib><creatorcontrib>Hatano, Etsuro</creatorcontrib><creatorcontrib>Toda, Rei</creatorcontrib><creatorcontrib>Nishino, Hiroto</creatorcontrib><creatorcontrib>Nakamura, Kojiro</creatorcontrib><creatorcontrib>Ishii, Takamichi</creatorcontrib><creatorcontrib>Seo, Satoru</creatorcontrib><creatorcontrib>Taura, Kojiro</creatorcontrib><creatorcontrib>Yasuchika, Kentaro</creatorcontrib><creatorcontrib>Yazawa, Takefumi</creatorcontrib><creatorcontrib>Zaima, Masazumi</creatorcontrib><creatorcontrib>Kanazawa, Akiyoshi</creatorcontrib><creatorcontrib>Terajima, Hiroaki</creatorcontrib><creatorcontrib>Kaihara, Satoshi</creatorcontrib><creatorcontrib>Adachi, Yukihito</creatorcontrib><creatorcontrib>Inoue, Naoya</creatorcontrib><creatorcontrib>Furumoto, Katsuyoshi</creatorcontrib><creatorcontrib>Manaka, Dai</creatorcontrib><creatorcontrib>Tokuka, Atsuo</creatorcontrib><creatorcontrib>Furuyama, Hiroaki</creatorcontrib><creatorcontrib>Doi, Koji</creatorcontrib><creatorcontrib>Hirose, Tetsuro</creatorcontrib><creatorcontrib>Horimatsu, Takahiro</creatorcontrib><creatorcontrib>Hasegawa, Suguru</creatorcontrib><creatorcontrib>Matsumoto, Shigemi</creatorcontrib><creatorcontrib>Sakai, Yoshiharu</creatorcontrib><creatorcontrib>Uemoto, Shinji</creatorcontrib><title>Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K‐RAS status for unresectable colorectal liver metastasis (BECK study): Long‐term results of survival</title><title>Journal of hepato-biliary-pancreatic sciences</title><addtitle>J Hepatobiliary Pancreat Sci</addtitle><description>Background/Purpose
To investigate the long‐term outcome and entire treatment course of patients with technically unresectable CRLM who underwent conversion hepatectomy and to examine factors associated with conversion to hepatectomy.
Methods
Recurrence and survival data with long‐term follow‐up were analyzed in the cohort of a multi‐institutional phase II trial for technically unresectable colorectal liver metastases (the BECK study).
Results
A total of 22/12 patients with K‐RAS wild‐type/mutant tumors were treated with mFOLFOX6 + cetuximab/bevacizumab. The conversion R0/1 hepatectomy rate was significantly higher in left‐sided primary tumors than in right‐sided tumors (75.0% vs 30.0%, P = .022). The median follow‐up was 72.6 months. The 5‐year overall survival (OS) rate in the entire cohort was 48.1%. In patients who underwent R0/1 hepatectomy (n = 21), the 5‐year RFS rate and OS rate were 19.1% and 66.3%, respectively. At the final follow‐up, seven patients had no evidence of disease, five were alive with disease, and 20 had died from their original cancer. All 16 patients who achieved 5‐year survival underwent conversion hepatectomy, and 11 of them underwent further resection for other recurrences (median: 2, range: 1‐4).
Conclusions
Conversion hepatectomy achieved a similar long‐term survival to the results of previous studies in initially resectable patients, although many of them experienced several post‐hepatectomy recurrences. Left‐sided primary was found to be the predictor for conversion hepatectomy.
Highlight
Okuno and colleagues report the final survival analysis of a multi‐institutional phase II trial for initially technically unresectable colorectal liver metastasis (BECK study). The 5‐year overall survival rate was 66.3% in patients who underwent conversion hepatectomy, which was the only independent prognostic factor for better overall survival on multivariate analysis.</description><subject>Colorectal cancer</subject><subject>colorectal liver metastases</subject><subject>conversion therapy</subject><subject>hepatic resection</subject><subject>Immunotherapy</subject><subject>Monoclonal antibodies</subject><subject>repeat hepatectomy</subject><subject>sidedness</subject><subject>Targeted cancer therapy</subject><subject>Tumors</subject><issn>1868-6974</issn><issn>1868-6982</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kctu1DAUhiMEolWpxBMgS2zKIm1sJ7HDrh11KO1Ig7hI7CLbOaEeOfHUlynDikfgjXgXngRH04uEhDf2sT5_58h_lr3ExTEuCnKyupbrY1ayJ9k-5jXP64aTpw9nVu5lh96virQopg0tnmd7lNCaFJjvZ79ndtyA89qOKFik7LA2EAA58KDCdHurwzUa5svFfPm13lUSNkLpH3EQElmHFIT4XU-FFB46lB5d_fn56-PpJ-SDCNGjPlFx3DmFNJD6GOumwiCjU380QBAJ9tqjo7Pz2VV6Gbvtm7doYcdvSRbADdNQ0QSPbI98dBu9EeZF9qwXxsPh3X6QfZmff55d5Ivlu_ez00WuygqzHDpCpeqU4nWPOWOYylI2vOxAyl4RVipBGDRV03NFG0gEk4JRLqGpRU9LepAd7bxrZ28i-NAO2iswRoxgo28JbTiuOGloQl__g65sdGOariUlrWhVVLx-FCpnvXfQt2uX_tBtW1y0U67tlGubck3oqzthlAN0D-B9ignId8CtNrD9r6i9vDj7MAn_AsDjsag</recordid><startdate>202008</startdate><enddate>202008</enddate><creator>Okuno, Masayuki</creator><creator>Hatano, Etsuro</creator><creator>Toda, Rei</creator><creator>Nishino, Hiroto</creator><creator>Nakamura, Kojiro</creator><creator>Ishii, Takamichi</creator><creator>Seo, Satoru</creator><creator>Taura, Kojiro</creator><creator>Yasuchika, Kentaro</creator><creator>Yazawa, Takefumi</creator><creator>Zaima, Masazumi</creator><creator>Kanazawa, Akiyoshi</creator><creator>Terajima, Hiroaki</creator><creator>Kaihara, Satoshi</creator><creator>Adachi, Yukihito</creator><creator>Inoue, Naoya</creator><creator>Furumoto, Katsuyoshi</creator><creator>Manaka, Dai</creator><creator>Tokuka, Atsuo</creator><creator>Furuyama, Hiroaki</creator><creator>Doi, Koji</creator><creator>Hirose, Tetsuro</creator><creator>Horimatsu, Takahiro</creator><creator>Hasegawa, Suguru</creator><creator>Matsumoto, Shigemi</creator><creator>Sakai, Yoshiharu</creator><creator>Uemoto, Shinji</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5708-6384</orcidid><orcidid>https://orcid.org/0000-0001-9539-8098</orcidid><orcidid>https://orcid.org/0000-0003-3407-1918</orcidid></search><sort><creationdate>202008</creationdate><title>Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K‐RAS status for unresectable colorectal liver metastasis (BECK study): Long‐term results of survival</title><author>Okuno, Masayuki ; Hatano, Etsuro ; Toda, Rei ; Nishino, Hiroto ; Nakamura, Kojiro ; Ishii, Takamichi ; Seo, Satoru ; Taura, Kojiro ; Yasuchika, Kentaro ; Yazawa, Takefumi ; Zaima, Masazumi ; Kanazawa, Akiyoshi ; Terajima, Hiroaki ; Kaihara, Satoshi ; Adachi, Yukihito ; Inoue, Naoya ; Furumoto, Katsuyoshi ; Manaka, Dai ; Tokuka, Atsuo ; Furuyama, Hiroaki ; Doi, Koji ; Hirose, Tetsuro ; Horimatsu, Takahiro ; Hasegawa, Suguru ; Matsumoto, Shigemi ; Sakai, Yoshiharu ; Uemoto, Shinji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4517-ed23bcdcc86f187713b4b984debbfc274ca27e959f8c39e8777ba738be96af343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Colorectal cancer</topic><topic>colorectal liver metastases</topic><topic>conversion therapy</topic><topic>hepatic resection</topic><topic>Immunotherapy</topic><topic>Monoclonal antibodies</topic><topic>repeat hepatectomy</topic><topic>sidedness</topic><topic>Targeted cancer therapy</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Okuno, Masayuki</creatorcontrib><creatorcontrib>Hatano, Etsuro</creatorcontrib><creatorcontrib>Toda, Rei</creatorcontrib><creatorcontrib>Nishino, Hiroto</creatorcontrib><creatorcontrib>Nakamura, Kojiro</creatorcontrib><creatorcontrib>Ishii, Takamichi</creatorcontrib><creatorcontrib>Seo, Satoru</creatorcontrib><creatorcontrib>Taura, Kojiro</creatorcontrib><creatorcontrib>Yasuchika, Kentaro</creatorcontrib><creatorcontrib>Yazawa, Takefumi</creatorcontrib><creatorcontrib>Zaima, Masazumi</creatorcontrib><creatorcontrib>Kanazawa, Akiyoshi</creatorcontrib><creatorcontrib>Terajima, Hiroaki</creatorcontrib><creatorcontrib>Kaihara, Satoshi</creatorcontrib><creatorcontrib>Adachi, Yukihito</creatorcontrib><creatorcontrib>Inoue, Naoya</creatorcontrib><creatorcontrib>Furumoto, Katsuyoshi</creatorcontrib><creatorcontrib>Manaka, Dai</creatorcontrib><creatorcontrib>Tokuka, Atsuo</creatorcontrib><creatorcontrib>Furuyama, Hiroaki</creatorcontrib><creatorcontrib>Doi, Koji</creatorcontrib><creatorcontrib>Hirose, Tetsuro</creatorcontrib><creatorcontrib>Horimatsu, Takahiro</creatorcontrib><creatorcontrib>Hasegawa, Suguru</creatorcontrib><creatorcontrib>Matsumoto, Shigemi</creatorcontrib><creatorcontrib>Sakai, Yoshiharu</creatorcontrib><creatorcontrib>Uemoto, Shinji</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of hepato-biliary-pancreatic sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Okuno, Masayuki</au><au>Hatano, Etsuro</au><au>Toda, Rei</au><au>Nishino, Hiroto</au><au>Nakamura, Kojiro</au><au>Ishii, Takamichi</au><au>Seo, Satoru</au><au>Taura, Kojiro</au><au>Yasuchika, Kentaro</au><au>Yazawa, Takefumi</au><au>Zaima, Masazumi</au><au>Kanazawa, Akiyoshi</au><au>Terajima, Hiroaki</au><au>Kaihara, Satoshi</au><au>Adachi, Yukihito</au><au>Inoue, Naoya</au><au>Furumoto, Katsuyoshi</au><au>Manaka, Dai</au><au>Tokuka, Atsuo</au><au>Furuyama, Hiroaki</au><au>Doi, Koji</au><au>Hirose, Tetsuro</au><au>Horimatsu, Takahiro</au><au>Hasegawa, Suguru</au><au>Matsumoto, Shigemi</au><au>Sakai, Yoshiharu</au><au>Uemoto, Shinji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K‐RAS status for unresectable colorectal liver metastasis (BECK study): Long‐term results of survival</atitle><jtitle>Journal of hepato-biliary-pancreatic sciences</jtitle><addtitle>J Hepatobiliary Pancreat Sci</addtitle><date>2020-08</date><risdate>2020</risdate><volume>27</volume><issue>8</issue><spage>496</spage><epage>509</epage><pages>496-509</pages><issn>1868-6974</issn><eissn>1868-6982</eissn><abstract>Background/Purpose
To investigate the long‐term outcome and entire treatment course of patients with technically unresectable CRLM who underwent conversion hepatectomy and to examine factors associated with conversion to hepatectomy.
Methods
Recurrence and survival data with long‐term follow‐up were analyzed in the cohort of a multi‐institutional phase II trial for technically unresectable colorectal liver metastases (the BECK study).
Results
A total of 22/12 patients with K‐RAS wild‐type/mutant tumors were treated with mFOLFOX6 + cetuximab/bevacizumab. The conversion R0/1 hepatectomy rate was significantly higher in left‐sided primary tumors than in right‐sided tumors (75.0% vs 30.0%, P = .022). The median follow‐up was 72.6 months. The 5‐year overall survival (OS) rate in the entire cohort was 48.1%. In patients who underwent R0/1 hepatectomy (n = 21), the 5‐year RFS rate and OS rate were 19.1% and 66.3%, respectively. At the final follow‐up, seven patients had no evidence of disease, five were alive with disease, and 20 had died from their original cancer. All 16 patients who achieved 5‐year survival underwent conversion hepatectomy, and 11 of them underwent further resection for other recurrences (median: 2, range: 1‐4).
Conclusions
Conversion hepatectomy achieved a similar long‐term survival to the results of previous studies in initially resectable patients, although many of them experienced several post‐hepatectomy recurrences. Left‐sided primary was found to be the predictor for conversion hepatectomy.
Highlight
Okuno and colleagues report the final survival analysis of a multi‐institutional phase II trial for initially technically unresectable colorectal liver metastasis (BECK study). The 5‐year overall survival rate was 66.3% in patients who underwent conversion hepatectomy, which was the only independent prognostic factor for better overall survival on multivariate analysis.</abstract><cop>Japan</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32362018</pmid><doi>10.1002/jhbp.747</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0001-5708-6384</orcidid><orcidid>https://orcid.org/0000-0001-9539-8098</orcidid><orcidid>https://orcid.org/0000-0003-3407-1918</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1868-6974 |
| ispartof | Journal of hepato-biliary-pancreatic sciences, 2020-08, Vol.27 (8), p.496-509 |
| issn | 1868-6974 1868-6982 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2398158293 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Colorectal cancer colorectal liver metastases conversion therapy hepatic resection Immunotherapy Monoclonal antibodies repeat hepatectomy sidedness Targeted cancer therapy Tumors |
| title | Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K‐RAS status for unresectable colorectal liver metastasis (BECK study): Long‐term results of survival |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T15%3A30%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Conversion%20to%20complete%20resection%20with%20mFOLFOX6%20with%20bevacizumab%20or%20cetuximab%20based%20on%20K%E2%80%90RAS%20status%20for%20unresectable%20colorectal%20liver%20metastasis%20(BECK%20study):%20Long%E2%80%90term%20results%20of%20survival&rft.jtitle=Journal%20of%20hepato-biliary-pancreatic%20sciences&rft.au=Okuno,%20Masayuki&rft.date=2020-08&rft.volume=27&rft.issue=8&rft.spage=496&rft.epage=509&rft.pages=496-509&rft.issn=1868-6974&rft.eissn=1868-6982&rft_id=info:doi/10.1002/jhbp.747&rft_dat=%3Cproquest_cross%3E2435350586%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2435350586&rft_id=info:pmid/32362018&rfr_iscdi=true |